Columbia Partners Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Columbia Partners Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,882	Closed	-$287K	–	344
2016 Q2	$287K	Sell	5,882 -31,504	-84%	-$2.04M	0.02%	332
2016 Q1	$2.37M	Sell	37,386 -27,702	-43%	-$1.81M	0.17%	164
2015 Q4	$7.3M	Sell	65,088 -1,728	-3%	-$173K	0.51%	71
2015 Q3	$6.43M	Sell	66,816 -22,294	-25%	-$2.55M	0.45%	88
2015 Q2	$9.12M	Sell	89,110 -5,342	-6%	-$415K	0.56%	66
2015 Q1	$5.86M	Buy	+94,452	New	+$5.25M	0.31%	122

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Columbia Partners Investment Management's RARE Position: Q3 2016 in Review

Columbia Partners Investment Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2016, closing a stake of 5,882 shares — an estimated $287K sold.

Columbia Partners Investment Management first reported a position in RARE in Q1 2015 and held it in 6 quarters. The position peaked at $9.12M in Q2 2015. 173 funds tracked by Wall St. Rank hold RARE as of Q3 2016.

Columbia Partners Investment Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2016 after selling out during the quarter.
Columbia Partners Investment Management sold 5,882 Ultragenyx Pharmaceutical shares in Q3 2016, an estimated $287K.
Columbia Partners Investment Management first reported a position in Ultragenyx Pharmaceutical in Q1 2015 and held it in 6 quarters.
Columbia Partners Investment Management's Ultragenyx Pharmaceutical position peaked at $9.12M in Q2 2015.
173 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2016.

Based on Columbia Partners Investment Management's 13F filing for Q3 2016, filed 14 Nov 2016.